DR.IBTISAM JALI MEDICAL DEMONSTRATOR

Slides:



Advertisements
Similar presentations
RHEUMATOID ARTHRITIS MUHAMMAD ADEEL (BIOT 412) Human Diseases Presentation.
Advertisements

Disease Modifying Anti-Rheumatic Drugs (DMARDs) Immunomodulatory and immunosuppresive Xenobiotic – Gold salts – Azathioprine – Methotrexate Biological.
NSAIDs 1 st line of therapy in the medical management of RA.
Rheumatoid Arthritis Systemic chronic inflammatory disease
Hatem H Eleishi, MD Professor of Rheumatology, Cairo University Consultant Rheumatologist, Dr. Soliman Fakeeh Hospital Rheumatoid Arthritis Wednesday,
Efficacy of Methotrexate and/or Etanercept for treatment of RA Rheumatoid Arthritis:
Anti-Inflammatory & Immunosuppressive Drugs 2
Hatem Eleishi, MD Rheumatologist STILL’S DISEASE.
Therapy of children with juvenile idiopathic arthritis. New drug therapy Rik Joos, M.D. Centre for Paediatric Rheumatology University hospital, Gent, Belgium.
Rheumatoid Arthritis “An Autoimmune Mystery” Cynthia Anderson.
Adult Still’s Disease Grant Paulsen AM Report May 22, 2009.
Management of Rheumatoid arthritis, Osteoarthritis & Gout Dr. Eoin Casey MD FRCPI, FRCP.
תרופות בשימוש בראומטולוגיה פרופ. משה טישלר מחלקה פנימית ב והשרות הראומטולוגי בי " ח אסף הרופא צריפין.
Drugs used in joint diseases
All About Rheumatoid Arthritis
Hot Topics in Rheumatology Prof. MG Molloy. Overview Rheumatoid Arthritis Psoriatic Arthritis Vasculitides: SLE Osteoarthritis Osteoporosis.
New Pharmacologic Treatment Options for Managing Rheumatoid Arthritis Devra Dang, Pharm.D. Department of Pharmacy National Institutes of Health.
Treatment of Rheumatoid Arthritis Then and Now
UC. Ulcerative Colitis ( UC ) Ulcerative colitis is an inflammatory bowel disease (IBD) that causes chronic inflammation of the digestive tract It is.
Inflammatory Bowel Disease Treatment. Epidemiology Clinical Laboratory Imaging Pathology Response to treatment IBD.
Disease –Modifying Antirheumatic Drugs ( DMARDs) Slow Acting Anti-inflammatory Drugs.
Interventions for Clients with Connective Tissue Disease and Other Types of Arthritis.
Cause of disability. Changes in the joint inflammation, proliferation of the synovium, errosion of cartilage & bones.
R HEUMATOID A RTHRITIS BMJ 2011;342: RA is a systemic inflammatory autoimmune disease with localised and general manifestations. It is characterised.
Recomendations for the medicamentous treatment of chronic inflammatory rheumatic disease pain Dušan Logar Dpt.of Rheumatology, University Clinical Centre,
Disease –Modifying Antirheumatic drugs
Copyright © 2013, 2010 by Saunders, an imprint of Elsevier Inc. Chapter 73 Drug Therapy of Rheumatoid Arthritis.
JRA is the most frequent chronic arthritis of children. The evidence of its was discovered from remained skeleton from 1000 years ago. It was prescribed.
1. Non-steroidal anti-inflammatory drugs (NSAIDs) 2. Glucocorticoids 3. Disease modifying anti-rheumatic drugs- DMARDs - imunosupressive effect -
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
Orthopedics Inflammatory Process Jan Bazner-Chandler RN, MSN, CNS, CPNP.
Rheumatoid Arthritis (RA) By: Leon Richardson Period
Interventions for Clients with Connective Tissue Disease and Other Types of Arthritis.
Adult Medical-Surgical Nursing Musculo-skeletal Module: Rheumatoid Arthritis.
LSU Clinical Pharmacology
Approach to the Treatment of RA Try to figure out ‘what type’ of Rheumatoid Arthritis the patient has This is not a uniform disease Young, Sero-positive.
Rheumatoid Arthritis Dr Chandini Rao Consultant Rheumatologist.
Elsevier items and derived items © 2006 by Elsevier Inc. Interventions for Clients with Connective Tissue Disease and Other Types of Arthritis.
( Slow Acting Anti-inflammatory Drugs ). OBJECTIVES At the end of the lecture the students should Define DMARDs Describe the classification of this group.
Dr. M Jokar RA - Definition u Chronic systemic inflammatory disorder u Unknown etiology u Synovium affected u Joint Deformity u Extra-articular.
Dr.B.V.Venkataraman Professor in Pharmacology International Medical School Faculti Perubatan, New BEL Rd Bangalore Drugs.
BY PROF. AZZA EL-MEDANY DR. OSAMA YOUSIF General Features & Conditions to use antirheumatic Low doses are commonly used early in the course of the disease.
Disease modified Anti-rheumatic drugs ( DMARD)
 Juvenile idiopathic arthritis (JIA) is the most common form of childhood arthritis and one of the more common chronic childhood illnesses. As the term.
Rheumatoid Arthritis Christine Aranyi and Rebecca Boon State university of new york institute of technology Pathophysiolog y Rheumatoid Arthritis (RA)
Advances in the Treatment of Crohn’s Disease GASTROENTEROLOGY 2004;126:1574–1581.
Treatment Goal of treatment reduce inflammation and pain, preservation of function, prevention of deformity.
Rheumatoid arthritis (RA).  Rheumatoid arthritis (RA) is a chronic, systemic inflammatory disorder that may affect many tissues and organs, but principally.
Disease Modifying Antirheumatic drugs. At the end of the lecture the students should: Know the pathogenesis of rheumatoid joint damage Emphasize the rational.
Juvenile Idiopathic Arthritis
DMARDs Disease-Modifying Anti rheumatic Drugs
Rheumatoid Arthritis: Management and New Therapies
Retinoids used in dermatology
Juvenile Idiopathic Arthritis
Monoclonal Antibodies
Treatment Goal of treatment reduce inflammation and pain
Epidemiology of rheumatoid arthritis
My Treatment Approach to Rheumatoid Arthritis
55 Rheumatoid arthritis.
Prediction of Response to Targeted Treatment in Rheumatoid Arthritis
Drug Therapy of Rheumatoid Arthritis
Rheumatology for the GP
Anti-tumor necrosis factor therapy
What’s new in my specialty- Rheumatoid Arthritis
Epidemiology of rheumatoid arthritis
Disease Modifying Anti-rheumatic drugs
Nat. Rev. Rheumatol. doi: /nrrheum
common rheumatologic diagnoses
Suggested therapeutic management according to subtypes and severity of rheumatic immune-related adverse events (irAE). *Add-on therapy with DMARDs (disease-modifying.
Presentation transcript:

DR.IBTISAM JALI MEDICAL DEMONSTRATOR JRA DR.IBTISAM JALI MEDICAL DEMONSTRATOR

Systemic Pauciarticular Polyarticular   Systemic Pauciarticular Polyarticular Percent of JRA patients 10-15 50 30-40 Sex F = M F > M Age any <17 years peak 2-3 years, rare >10 peaks 2-5, 10-14 years Joints any large joints, but rarely hips any, rare to start in hip Fever, rash, lymphadenopathy, hepatosplenomegaly yes no Uveitis rare 20 percent, esp ANA + less frequent Laboratory abnormalities Leukocytosis marked Anemia mild Elevated ESR ANA absent low titer common low titer common in younger Rheumatoid factor 10-20 percent in those >10 years Destructive arthritis >50 percent Disease modifying drug commonly used rarely used

PAUCIARTICULAR JRA True pauciarticular onset JRA is usually responsive to (NSAIDs). Methotrexate and other immunosuppressive drugs are rarely, if ever, required. patients does not respond to NSAIDs or intra-articular steroid injections, may benefit from methotrexate or anti TNF (eg, etanercept or adalimumab). (extended pauciarticular subset) additional joint involvement after an initial pauciarticular onset low-dose oral methotrexate may be effective

POLYARTICULAR JRA Initial therapy with NSAIDs, If there is no response to the initial NSAID by three weeks, the first NSAID is discontinued and a second NSAID is started. If the patient continues to be unresponsive to NSAID therapy alone, a second line drug is recommended; methotrexate at a dose of 10mg/m2 BSA/week or anti-TNF. Corticosteroids; Systemic, Injection  Leflunomide not FDA approved for pediatric use Sulfasalazine has been shown to be beneficial for many children with polyarticular JRA Sulfasalazine does not prevent chronic changes and therefore should not be relied upon in erosive disease adalimumab approved by the FDA for the treatment of moderate to severe JRA Infliximab (Remicade®), a chimeric mouse-human monoclonal antibody with affinity for TNF-alpha. It is not approved by the FDA for treatment of JRA. Abatacept (Orencia) has recently been approved by the United States FDA for the treatment of JRA

SYSTEMIC JRA Nonsteroidal anti-inflammatory drugs (NSAIDs) alone are effective for many children with systemic onset JRA. If NSAIDs are ineffective, second line agents such as corticosteroids, or methotrexate may be considered. For those with the most difficult disease which is refractory to conventional therapy, biologic agents are used. Infliximab and adalimumab, monoclonal antibodies to TNF alpha also have been used with varying success in children with systemic JRA biological agents that target IL-1 and IL-6 activity, such as anakinra and thalidomide, human recombinant anti-interleukin-6 monoclonal antibody; MRA, tocilizumab, atlizumab Cyclosporine has received increased attention over the past few years in systemic onset JRA. apparent usefulness in the treatment of DIC/macrophage activation syndrome bone marrow transplantation should be restricted to only the most severely affected children

Macrophage activation syndrome Macrophage activation syndrome — severe and life-threatening complication of systemic JRA, typically occurs within the first few days or weeks following the initiation of therapy with aspirin, other nonsteroidal antiinflammatory drugs, sulfasalazine, or gold salts. may follow viral and bacterial infections, or occur without any evident initiating event. It is thought to be caused by the activation of T lymphocytes and macrophages, resulting in the uncontrolled release of inflammatory cytokines ("cytokine storm"). Children may present with spontaneous bleeding, bruising, or shock. The hemoglobin, platelet count, and serum fibrinogen typically drop precipitously secondary to consumptive coagulopathy. Fibrin split products in the peripheral circulation are generally the earliest confirmatory sign of DIC. Treatment consists of fresh frozen plasma, corticosteroids, and supportive care. All NSAIDs and other antirheumatic medications should be withdrawn since they may exacerbate the illness except corticosteroids and cyclosporine.

THANKS